BMJ mental health最新文献

{"title":"Chronotype and emotion processing: a pilot study testing timing of online cognitive bias modification training.","authors":"Charlotte M Crisp, Emily Mooney, Mohini Howlader, Joel Stoddard, Ian Penton-Voak","doi":"10.1136/bmjment-2024-301045","DOIUrl":"10.1136/bmjment-2024-301045","url":null,"abstract":"<p><strong>Background: </strong>Circadian rhythms influence cognitive performance which peaks in the morning for early chronotypes and evening for late chronotypes. It is unknown whether cognitive interventions are susceptible to such synchrony effects and could be optimised at certain times-of-day.</p><p><strong>Objective: </strong>A pilot study testing whether the effectiveness of cognitive bias modification (CBM) for facial emotion processing was improved when delivered at a time-of-day that was synchronised to chronotype.</p><p><strong>Methods: </strong>173 healthy young adults (aged 18-25) with an early or late chronotype completed one online session of CBM training in either the morning (06:00 hours to 10:00 hours) or evening (18:00 hours to 22:00 hours).</p><p><strong>Findings: </strong>Moderate evidence that participants learnt better (higher post-training balance point) when they completed CBM training in the synchronous (evening for late chronotypes, morning for early chronotypes) compared with asynchronous (morning for late chronotypes, evening for early chronotypes) condition, controlling for pre-training balance point, sleep quality and negative affect. There was also a group×condition interaction where late chronotypes learnt faster and more effectively in synchronous versus asynchronous conditions.</p><p><strong>Conclusions: </strong>Preliminary evidence that synchrony effects apply to this psychological intervention. Tailoring the delivery timing of CBM training to chronotype may optimise its effectiveness. This may be particularly important for late chronotypes who were less able to adapt to non-optimal times-of-day, possibly because they experience more social jetlag.</p><p><strong>Clinical implications: </strong>To consider delivery timing of CBM training when administering to early and late chronotypes. This may generalise to other psychological interventions and be relevant for online interventions where the timing can be flexible.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suicide deaths associated with climate change-induced heat anomalies in Australia: a time series regression analysis.","authors":"Lucas Hertzog, Fiona Charlson, Petra Tschakert, Geoffrey G Morgan, Richard Norman, Gavin Pereira, Ivan C Hanigan","doi":"10.1136/bmjment-2024-301131","DOIUrl":"10.1136/bmjment-2024-301131","url":null,"abstract":"<p><strong>Background: </strong>Although environmental determinants play an important role in suicide mortality, the quantitative influence of climate change-induced heat anomalies on suicide deaths remains relatively underexamined.</p><p><strong>Objective: </strong>The objective is to quantify the impact of climate change-induced heat anomalies on suicide deaths in Australia from 2000 to 2019.</p><p><strong>Methods: </strong>A time series regression analysis using a generalised additive model was employed to explore the potentially non-linear relationship between temperature anomalies and suicide, incorporating structural variables such as sex, age, season and geographic region. Suicide deaths data were obtained from the Australian National Mortality Database, and gridded climate data of gridded surface temperatures were sourced from the Australian Gridded Climate Dataset.</p><p><strong>Findings: </strong>Heat anomalies in the study period were between 0.02°C and 2.2°C hotter than the historical period due to climate change. Our analysis revealed that approximately 0.5% (264 suicides, 95% CI 257 to 271) of the total 50 733 suicides within the study period were attributable to climate change-induced heat anomalies. Death counts associated with heat anomalies were statistically significant (p value 0.03) among men aged 55+ years old. Seasonality was a significant factor, with increased deaths during spring and summer. The relationship between high heat anomalies and suicide deaths varied across different demographic segments.</p><p><strong>Conclusions and implications: </strong>This study highlights the measurable impact of climate change-induced heat anomalies on suicide deaths in Australia, emphasising the need for increased climate change mitigation and adaptation strategies in public health planning and suicide prevention efforts focusing on older adult men. The findings underscore the importance of considering environmental factors in addition to individual-level factors in understanding and reducing suicide mortality.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acceptability, use and safety of the BlueIce self-harm prevention app: qualitative findings from the Beating Adolescent Self-Harm (BASH) randomised controlled trial.","authors":"Paul Stallard, Kathryn Whittle, Emma Moore, Antonieta Medina-Lara, Nia Morrish, Shelley Rhodes, Gordon Taylor, Bethany Cliffe","doi":"10.1136/bmjment-2023-300961","DOIUrl":"10.1136/bmjment-2023-300961","url":null,"abstract":"<p><strong>Background: </strong>Little is known about the social validity of self-harm prevention apps for young adolescents with severe mental health problems who repeatedly self-harm.</p><p><strong>Objective: </strong>We assessed the acceptability, use and safety of BlueIce, a self-harm prevention app for young adolescents who self-harm.</p><p><strong>Methods: </strong>Mixed methods study involving a content analysis of postuse interviews. Participants were a clinical group of 60 UK adolescents aged 12-17 with repeated self-harm, randomised to receive BlueIce.</p><p><strong>Findings: </strong>BlueIce was used by 57/60 (95%) respondents with 47/57 (82%) using BlueIce when thinking about self-harm. 17/47 (36%) who were thinking about self-harm used it on more than six occasions with 36/47 (77%) reporting that BlueIce prevented at least one episode of self-harm. 33/47 (70%) reported occasions when they used the app but still went on to self-harm. Reasons why the app was not used or not helpful included feeling too distressed, a negative mindset, prior decision to self-harm or forgetting. BlueIce was rated 4.09 (SD=0.75) out of 5 stars, with high mean ratings out of 10 for ease of use (8.70, SD=1.37) and good for acceptability (7.68, SD=2.05) and helpfulness (6.77, SD=1.72). No respondent identified BlueIce as triggering any episode of self-harm.</p><p><strong>Conclusion: </strong>These findings are consistent with previous evaluations and highlight the acceptability, use and safety of BlueIce. Self-reports indicate that BlueIce prevented some episodes of self-harm.</p><p><strong>Clinical implications: </strong>Our results highlight the acceptability of the BlueIce self-harm app for young adolescents who repeatedly self-harm.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11202734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the minimal important difference in the treatment of paediatric obsessive-compulsive disorder using selective serotonin reuptake inhibitors.","authors":"Sem E Cohen, Damiaan A J P Denys, Taina Kristiina Mattila, Bram W C Storosum, Anthonius de Boer, Jasper Brian Zantvoord","doi":"10.1136/bmjment-2024-300999","DOIUrl":"10.1136/bmjment-2024-300999","url":null,"abstract":"","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141433486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe psychiatric disorders are associated with increased risk of dementia.","authors":"Joshua Stevenson-Hoare, Sophie E Legge, Emily Simmonds, Jun Han, Michael J Owen, Michael O'Donovan, George Kirov, Valentina Escott-Price","doi":"10.1136/bmjment-2024-301097","DOIUrl":"10.1136/bmjment-2024-301097","url":null,"abstract":"<p><strong>Background: </strong>Individuals with psychiatric disorders have an increased risk of developing dementia. Most cross-sectional studies suffer from selection bias, underdiagnosis and poor population representation, while there is only limited evidence from longitudinal studies on the role of anxiety, bipolar and psychotic disorders. Electronic health records (EHRs) permit large cohorts to be followed across the lifespan and include a wide range of diagnostic information.</p><p><strong>Objective: </strong>To assess the association between four groups of psychiatric disorders (schizophrenia, bipolar disorder/mania, depression and anxiety) with dementia in two large population-based samples with EHR.</p><p><strong>Methods: </strong>Using EHR on nearly 1 million adult individuals in Wales, and from 228 937 UK Biobank participants, we studied the relationships between schizophrenia, mania/bipolar disorder, depression, anxiety and subsequent risk of dementia.</p><p><strong>Findings: </strong>In Secure Anonymised Information Linkage, there was a steep increase in the incidence of a first diagnosis of psychiatric disorder in the years prior to the diagnosis of dementia, reaching a peak in the year prior to dementia diagnosis for all psychiatric diagnoses. Psychiatric disorders, except anxiety, were highly significantly associated with a subsequent diagnosis of dementia: HRs=2.87, 2.80, 1.63 for schizophrenia, mania/bipolar disorder and depression, respectively. A similar pattern was found in the UK Biobank (HRs=4.46, 3.65, 2.39, respectively) and anxiety was also associated with dementia (HR=1.34). Increased risk of dementia was observed for all ages at onset of psychiatric diagnoses when these were divided into 10-year bins.</p><p><strong>Conclusions: </strong>Psychiatric disorders are associated with an increased risk of subsequent dementia, with a greater risk of more severe disorders.</p><p><strong>Clinical implications: </strong>A late onset of psychiatric disorders should alert clinicians of possible incipient dementia.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11184176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in the prevalence of mental health problems during the first year of the pandemic: a systematic review and dose-response meta-analysis.","authors":"Georgia Salanti, Natalie Luise Peter, Thomy Tonia, Alexander Holloway, Leila Darwish, Ronald C Kessler, Ian White, Simone N Vigod, Matthias Egger, Andreas D Haas, Seena Fazel, Helen Herrman, Christian Kieling, Vikram Patel, Tianjing Li, Pim Cuijpers, Andrea Cipriani, Toshi A Furukawa, Stefan Leucht","doi":"10.1136/bmjment-2024-301018","DOIUrl":"10.1136/bmjment-2024-301018","url":null,"abstract":"<p><strong>Aim: </strong>To describe the pattern of the prevalence of mental health problems during the first year of the COVID-19 pandemic and examine the impact of containment measures on these trends.</p><p><strong>Methods: </strong>We identified articles published until 30 August 2021 that reported the prevalence of mental health problems in the general population at two or more time points. A crowd of 114 reviewers extracted data on prevalence, study and participant characteristics. We collected information on the number of days since the first SARS-CoV-2 infection in the study country, the stringency of containment measures and the number of cases and deaths. We synthesised changes in prevalence during the pandemic using a random-effects model. We used dose-response meta-analysis to evaluate the trajectory of the changes in mental health problems.</p><p><strong>Results: </strong>We included 41 studies for 7 mental health conditions. The average odds of symptoms increased during the pandemic (mean OR ranging from 1.23 to 2.08). Heterogeneity was very large and could not be explained by differences in participants or study characteristics. Average odds of psychological distress, depression and anxiety increased during the first 2 months of the pandemic, with increased stringency of the measures, reported infections and deaths. The confidence in the evidence was low to very low.</p><p><strong>Conclusions: </strong>We observed an initial increase in the average risk of psychological distress, depression-related and anxiety-related problems during the first 2 months of the pandemic. However, large heterogeneity suggests that different populations had different responses to the challenges imposed by the pandemic.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141322046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric traumatic brain injury and attention-deficit/hyperactivity disorder medication in Finland: a nationwide register-based cohort study.","authors":"Juho Laaksonen, Ville Ponkilainen, Julius Möttönen, Ville M Mattila, Ilari Kuitunen","doi":"10.1136/bmjment-2024-301083","DOIUrl":"10.1136/bmjment-2024-301083","url":null,"abstract":"<p><strong>Background: </strong>The association between paediatric traumatic brain injury (pTBI) and post-traumatic attention-deficit/hyperactivity disorder (ADHD) medication usage remains understudied subject.</p><p><strong>Objective: </strong>We aimed to evaluate the association between pTBI and subsequent ADHD medication.</p><p><strong>Methods: </strong>A nationwide retrospective cohort study in Finland from 1998 to 2018 included 66 594 patients with pTBI and 61 412 references with distal extremity fractures. ADHD medication data were obtained from the Finnish Social Insurance Institution. The primary outcome was post-traumatic pediatric ADHD medication. A 1-year washout period was applied, and follow-up started 1 year post-pTBI.</p><p><strong>Findings: </strong>Kaplan-Meier analyses showed higher ADHD medication usage in patients with pTBI, especially post-operatively. Both sex groups exhibited elevated rates compared with the reference group. Over 10 years, cumulative incidence rates were 3.89% (pTBI) vs 1.90% (reference). HR for pTBI was 1.89 (95% CI 1.70 to 2.10) after 4 years and 6.31 (95% CI 2.80 to 14.20) for the operative group after the initial follow-up year. After 10 years, cumulative incidence in females increased to 2.14% (pTBI) vs 1.07% (reference), and in males, to 5.02% (pTBI) vs 2.35% (reference). HR for pTBI was 2.01 (95% CI 1.72 to 2.35) in females and 2.23 (95% CI 2.04 to 2.45) in males over 1-20 years.</p><p><strong>Conclusions: </strong>A substantial association between pTBI and post-traumatic ADHD medication was evidenced over a 20-year follow-up period.</p><p><strong>Clinical implications: </strong>These results stress the need for preventive measures for pTBI and highlight the potential impact of long-term post-traumatic monitoring and psychoeducation.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis.","authors":"Jack Christopher Wilson, Kathy Y Liu, Katherine Jones, Jansher Mahmood, Utkarsh Arya, Rob Howard","doi":"10.1136/bmjment-2024-301017","DOIUrl":"10.1136/bmjment-2024-301017","url":null,"abstract":"<p><strong>Question: </strong>Does neurodegenerative disease underlie the increased rate of dementia observed in older people with schizophrenia? Several studies have reported a higher prevalence of dementia in people with schizophrenia compared with the general population. This may reflect a higher risk of developing neurodegenerative diseases such as vascular dementia or Alzheimer's disease (AD). Alternatively, this may reflect non-pathological, age-related cognitive decline in a population with low cognitive reserve.</p><p><strong>Study selection and analysis: </strong>We reviewed papers that compared postmortem findings, hippocampal MRI volume or cerebrospinal fluid (CSF) markers of AD, between patients with schizophrenia with evidence of cognitive impairment (age ≥45 years) with controls. We subsequently performed a meta-analysis of postmortem studies that compared amyloid-β plaques (APs) or neurofibrillary tangles (NFTs) in cognitively impaired patients with schizophrenia to normal controls or an AD group.</p><p><strong>Findings: </strong>No studies found a significant increase of APs or NFTs in cognitively impaired patients with schizophrenia compared with controls. All postmortem studies that compared APs or NFTs in patients with schizophrenia to an AD group found significantly more APs or NFTs in AD. No studies found a significant differences in CSF total tau or phosphorylated tau between patients with schizophrenia and controls. The two studies which compared CSF Aβ42 between patients with schizophrenia and controls found significantly decreased CSF Aβ42 in schizophrenia compared with controls. Hippocampal volume findings were mixed.</p><p><strong>Conclusions: </strong>Studies have not found higher rates of AD-related pathology in cognitively impaired individuals with schizophrenia compared with controls. Higher rates of dementia identified in population studies may reflect a lack of specificity in clinical diagnostic tools used to diagnose dementia.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11129036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypersexuality in neurological disorders: A systematic review.","authors":"Natalie Tayim, Pedro Barbosa, Jalesh Panicker","doi":"10.1136/bmjment-2024-300998","DOIUrl":"10.1136/bmjment-2024-300998","url":null,"abstract":"<p><strong>Background: </strong>Hypersexuality (HS) accompanying neurological conditions remains poorly characterized despite profound psychosocial impacts. <b>Objective</b> We aimed to systematically review the literature on HS in patients with neurological disorders. <b>Study selection and analysis</b> We conducted a systematic review to identify studies that reported HS in neurological disorders. HS was defined as a condition characterized by excessive and persistent preoccupation with sexual thoughts, urges, and behaviors that cause significant distress or impairment in personal, social, or occupational functioning. Data on demographics, assessment techniques, associated elements, phenotypic manifestations, and management strategies were also extracted. <b>Findings</b> The final analysis included 79 studies on HS, encompassing 32 662 patients across 81 cohorts with neurological disorders. Parkinson's disease was the most frequently studied condition (55.6%), followed by various types of dementia (12.7%). Questionnaires were the most common assessment approach for evaluating HS, although the techniques varied substantially. Alterations in the dopaminergic pathways have emerged as contributing mechanisms based on the effects of medication cessation. However, standardized treatment protocols still need to be improved, with significant heterogeneity in documented approaches. Critical deficiencies include risks of selection bias in participant sampling, uncontrolled residual confounding factors, and lack of blinded evaluations of reported outcomes. <b>Conclusions and clinical implications</b> Despite growth in the last decade, research on HS remains limited across neurological conditions, with lingering quality and methodological standardization deficits. Key priorities include advancing assessment tools, elucidating the underlying neurobiology, and formulating management guidelines.</p><p><strong>Prospero registration number: </strong>CRD42017036478.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality and adverse events associated with statin use in primary care patients with depression: a real-world, population-based cohort study.","authors":"Riccardo De Giorgi, Franco De Crescenzo, Edoardo Giuseppe Ostinelli, Philip J Cowen, Catherine J Harmer, Seena Fazel, Andrea Cipriani","doi":"10.1136/bmjment-2024-301035","DOIUrl":"10.1136/bmjment-2024-301035","url":null,"abstract":"<p><strong>Background: </strong>New National Institute for Health and Care Excellence (NICE) guidance endorses the prescription of statins in larger population groups for the prevention of cardiovascular and cerebrovascular morbidity and mortality, especially in people with severe mental illness. However, the evidence base for their safety and risk/benefit balance in depression is not established.</p><p><strong>Objectives: </strong>This study aims to assess the real-world mortality and adverse events of statins in depressive disorders.</p><p><strong>Methods: </strong>Population-based, nationwide (England), between-subject, cohort study. We used electronic health records (QResearch database) of people aged 18-100 years with first-episode depression, registered with English primary care practices over January 1998-August 2020 for 12(+) months, divided into statin users versus non-users.Primary safety outcomes included all-cause mortality and any adverse event measured at 2, 6 and 12 months. Multivariable logistic regression was employed to control for several potential confounders and calculate adjusted ORs (aORs) with 99% CIs.</p><p><strong>Findings: </strong>From over 1 050 105 patients with depression (42.64% males, mean age 43.23±18.32 years), 21 384 (2.04%) died, while 707 111 (67.34%) experienced at least one adverse event during the 12-month follow-up. Statin use was associated with lower mortality over 12 months (range aOR_2-12months 0.66-0.67, range 99% CI 0.60 to 0.73) and with lower adverse events over 6 months (range aOR_2-6months 0.90-0.96, range 99% CI 0.91 to 0.99), but not at 1 year (aOR_12months 0.99, 99% CI 0.96 to 1.03). No association with any other individual outcome measure (ie, any other neuropsychiatric symptoms) was identified.</p><p><strong>Conclusions: </strong>We found no evidence that statin use among people with depression increases mortality or other adverse events.</p><p><strong>Clinical implications: </strong>Our findings support the safety of updated NICE guidelines for prescribing statins in people with depressive disorders.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}